Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Michael H. Mulroy sold 10,000 shares of the stock on the open market in a transaction dated Thursday, April 10th. The stock was sold at an average price of $85.04, for a total transaction of $850,400.00. Following the transaction, the insider now directly owns 77,063 shares in the company, valued at approximately $6,553,438. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) shares after opening at $80.05 moved to $81.93 on last trade day and at the end of the day closed at $78.38. Company price to sales ratio in past twelve months was calculated as 5.94 and price to cash ratio as 19.38. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) showed a negative weekly performance of -2.73%.
Illumina (NASDAQ:ILMN) CEO Jay Flatley sold 30,000 shares of the stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $139.90, for a total transaction of $4,197,000.00. Following the completion of the sale, the chief executive officer now directly owns 381,262 shares of the company’s stock, valued at approximately $53,338,554. Illumina, Inc. (NASDAQ:ILMN) shares fell -2.44% in last trading session and ended the day on $131.94. ILMN return on equity ratio is recorded as 8.90% and its return on assets is 4.40%. Illumina, Inc. (NASDAQ:ILMN) yearly performance is 137.47%.
Vertex Pharmaceuticals (NASDAQ:VRTX) Director Elaine Ullian sold 2,500 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $70.00, for a total value of $175,000.00. Following the sale, the director now directly owns 5,265 shares in the company, valued at approximately $368,550. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares moved down -0.98% in last trading session and was closed at $62.44, while trading in range of $61.19 – $65.14. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) year to date (YTD) performance is -15.96%.
Endocyte (NASDAQ:ECYT) VP Allen Ritter sold 1,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $21.16, for a total value of $21,160.00. Following the completion of the sale, the vice president now directly owns 34,282 shares in the company, valued at approximately $725,407. Endocyte, Inc. (NASDAQ:ECYT) weekly performance is -15.54%. On last trading day company shares ended up $18.48. Endocyte, Inc. (NASDAQ:ECYT) distance from 50-day simple moving average (SMA50) is 10.18%. Analysts mean target price for the company is $42.17.